


4 TIME-SAVING SOLUTIONS TO COMMON EARLY DEVELOPMENT CHALLENGES

In the race to market, you need fast, cost-effective, and scientifically proven solutions to seamlessly guide your molecule through early-phase development. Explore these five flexible solutions that enable you to move your molecule through each early development phase with efficiency and speed.


 **INTERACTIVE GRAPHIC: Hover over arrows to reveal more details**

1. Predictive modeling for formulation challenges

You're struggling with the formulation of your molecule but do not have the time and resources to test multiple formulation options. Quadrant 2™ can solve solubility and bioavailability challenges before they become long term issues.



Early success




Faster results

We have analyzed 250+ molecules using Quadrant 2™ for bioavailability challenges.


1 Source: GlobalData, Pharma Intelligence Center Drug Database

2. Formulation enabling technologies

You know the formulation technology your molecule needs for optimal efficacy, but you lack the manufacturing technologies necessary. You need an experienced partner who can provide the expertise and specialized technology needed to successfully deliver your product. We can provide:




Expertise




Capabilities

3. End-to-end solution to shorten timelines

You need to take your discovered molecule through development and IND/IMPD as quickly as possible. Utilizing a single-source, integrated development program, such as Quick to Clinic™, will accelerate your timeline and ensure critical details are not overlooked.




Accelerated timelines




Optimized workflow

4. Comprehensive regulatory strategy

You want to ensure that you can swiftly and successfully manage the complex regulatory environment while balancing speed, risk, and future needs of a regional and global launch. By leveraging our regulatory experts, we can assist you in filing your submission and developing your regulatory strategy.




Integrated regulatory services



Shortened timelines

2 Source: A. DiMasi, Z. Smith, and K.A. Getz, "Assessing the Economics of Single-Source vs. Multi-Vendor Manufacturing," Tufts Center for the Study of Drug Development

 We can provide you with customized early development strategies and technical solutions leveraging our years of experience and expertise in solving complex development challenges. **Contact us today.**